P.A.W. Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

P.A.W. Capital’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-200,000	Closed	-$740K	–	64
2017 Q4	$740K	Sell	200,000 -40,000	-17%	-$164K	0.93%	37
2017 Q3	$982K	Buy	+240,000	New	+$918K	1.03%	41

P.A.W. Capital's CASC Position: Q1 2018 in Review

P.A.W. Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 200,000 shares — an estimated $740K sold.

P.A.W. Capital first reported a position in CASC in Q3 2017 and held it in 2 quarters. The position peaked at $982K in Q3 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

P.A.W. Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
P.A.W. Capital sold 200,000 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $740K.
P.A.W. Capital first reported a position in Cascadian Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
P.A.W. Capital's Cascadian Therapeutics, Inc. position peaked at $982K in Q3 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on P.A.W. Capital's 13F filing for Q1 2018, filed 26 Apr 2018.